Trial · NCT03167242
Adverse events240
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 240
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | PK Run-in: KAF 200 mg and LUM 960 mg QD for 1 Day | 0 | 12 | |
| other | Anaemia | Blood and lymphatic system disorders | Part A: KAF 800 mg and LUM 960 mg QD for 1 Day | 0 | 51 | |
| other | Anaemia | Blood and lymphatic system disorders | Part A: KAF 200 mg and LUM 480 mg QD for 3 Days | 1 | 54 | |
| other | Anaemia | Blood and lymphatic system disorders | Part A: KAF 400 mg and LUM 480 mg QD for 3 Days | 1 | 51 | |
| other | Anaemia | Blood and lymphatic system disorders | Part A and Part B: KAF 400 mg and LUM 960 mg QD for 1 Day | 5 | 103 | |
| other | Anaemia | Blood and lymphatic system disorders | Part A and Part B: KAF 400 mg and LUM 960 mg QD for 2 Days | 3 | 104 | |
| other | Anaemia | Blood and lymphatic system disorders | Part A and Part B: KAF 400 mg and LUM 960 mg QD for 3 Days | 5 | 97 | |
| other | Anaemia | Blood and lymphatic system disorders | Part A and Part B: Coartem | 1 | 51 | |
| other | Eosinophilia | Blood and lymphatic system disorders | PK Run-in: KAF 200 mg and LUM 960 mg QD for 1 Day | 0 | 12 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Part A: KAF 800 mg and LUM 960 mg QD for 1 Day | 2 | 51 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Part A: KAF 200 mg and LUM 480 mg QD for 3 Days | 3 | 54 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Part A: KAF 400 mg and LUM 480 mg QD for 3 Days | 2 | 51 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Part A and Part B: KAF 400 mg and LUM 960 mg QD for 1 Day | 0 | 103 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Part A and Part B: KAF 400 mg and LUM 960 mg QD for 2 Days | 1 | 104 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Part A and Part B: KAF 400 mg and LUM 960 mg QD for 3 Days | 3 | 97 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Part A and Part B: Coartem | 0 | 51 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | PK Run-in: KAF 200 mg and LUM 960 mg QD for 1 Day | 0 | 12 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Part A: KAF 800 mg and LUM 960 mg QD for 1 Day | 3 | 51 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Part A: KAF 200 mg and LUM 480 mg QD for 3 Days | 1 | 54 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Part A: KAF 400 mg and LUM 480 mg QD for 3 Days | 5 | 51 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03167242/events